Arbutus Biopharma falls on FDA clinical hold for immune drug trial

Arbutus Biopharma

25/04/2023 16:27

** Shares of biopharma co Arbutus Biopharma  ABUS.O  down
11.9% at $2.5
    ** Says FDA has placed its application to start trials on
its immunity booster drug on hold
    ** Co's drug candidate, AB-101, is designed to boost the
immune system of patients with chronic hepatitis B virus
    ** Says FDA indicated to provide official clinical hold
letter within 30 days 
    ** "We no longer intends to report initial data from
early-stage trial in H2 2023" - Arbutus
    ** ABUS stock up 10.1% YTD

 (Reporting by Nandhini Srinivasan in Bengaluru)
 ((nandhini.srinivasan@thomsonreuters.com))